Radiation-Induced Fibrosis (RIF) in Head and Neck Squamous Cell Carcinoma (HNSCC): A Review

Area of Science:

• Oncology
• Radiation Oncology
• Fibrosis Research

Background:

• Radiation-induced fibrosis (RIF) affects up to 50% of head and neck squamous cell carcinoma (HNSCC) patients post-radiation therapy (RT).
• Current frontline treatment (Pentoxifylline and Vitamin E - PENTOX) offers palliation but limited anti-fibrotic effects.
• Existing therapies like hyperbaric oxygen show limited impact on fibrotic burden.

Purpose of the Study:

• To review the pathogenesis of RIF in HNSCC.
• To summarize potential anti-fibrotic agents for RIF in HNSCC.

Main Methods:

• Literature review of RIF pathogenesis and treatment strategies.
• Analysis of experimental data on novel anti-fibrotic agents.
• Focus on agents with potential application in HNSCC.

Main Results:

• RIF involves aberrant myofibroblast activation post-RT.
• PENTOX provides symptomatic relief but has limited efficacy in reducing fibrosis.
• Emerging therapies including natural antioxidants, agents for idiopathic pulmonary fibrosis, and stem cell therapy show promise but require HNSCC-specific studies.

Conclusions:

• Understanding RIF pathogenesis is crucial for developing targeted therapies.
• Further research is needed to validate novel anti-fibrotic agents for HNSCC patients.
• Future strategies may involve combination therapies to effectively manage RIF.